01.13.22 -- Listen Now: CAR T Manufacturing Control, Genome Engineering of Hematopoietic Stem Cells, and more!

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters including our podcast series. Don’t forget to subscribe so you never miss an episode!

Vor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs, and the cell manufacturing process needed to leverage genome engineering technologies for the cells they're creating.

Fernanda Copeland, global head, patient advocacy and engagement at AVROBIO, explains how to incorporate community education, patient feedback, and more to improve clinical trial development and recruitment.

Join your host Matt Pillar and guest Allan Shaw for a no-holds-barred retrospective on the year's top stories and trends. From the frontlines of the COVID-19 pandemic to the questionable approval of Aduhelm to leadership instability at the FDA and more, Shaw dissects the year past and predicts how those stories will influence the biotech industry in 2022 and beyond.

Cellectis' decision to build and operate its own trans-Atlantic manufacturing facilities was a strategic one. Here, SVP of U.S. manufacturing Steve Doares talks internal manufacturing rationale, discusses interoperability between its Paris and Raleigh, NC, plants, and shares how the company keeps meeting the challenges presented by COVID-19-fueled supply chain disruptions head-on.

Elevation Oncology is improving both the accuracy of and accessibility to genomic testing for cancer patients. In tandem, the company is in the clinic with its lead candidate seribantumab for cancer patients with solid tumors that express a genomic change called an NRG1 fusion. Founder and CEO Shawn Leland, PharmD, RPh, shares the company's unique approach. 

Glenn Mattes' TFF Pharmaceuticals is looking to break the parenteral barrier by manufacturing biologics — monoclonal antibodies (mAbs) and vaccines, more specifically — that can be inhaled, rather than injected. It's a timely endeavor, and TFF's business model is a collaborative one that seeks to explore dry powder biologics options through partnership, in addition to its own pipeline.

Lumen Bioscience's cofounder and CEO, Brian Finrow, J.D., and EVP of production/development, Craig Behnke, Ph.D., discuss the development of therapeutic proteins from readily available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.